Publications by authors named "J M Rabasa"
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
Reumatol Clin (Engl Ed)
March 2022
Objective: To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Methods: Medical records of patients admitted with COVID19 and IP with PaO/FiO<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Results: Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51-70: 30%; >70: 53%), with 8.
Objective: The aim was to evaluate the cytology, colposcopic, and pathological factors associated with the absence of high-grade squamous intraepithelial lesion (HSIL)/cervical intraepithelial neoplasia (CIN) 2-3 lesion on loop electrosurgical excision procedure (LEEP) specimens in women with high-grade cytology and/or HSIL/CIN 2-3 biopsy and the risk of disease persistence/recurrence.
Materials And Methods: Two-center retrospective study of women undergoing LEEP for high-grade cervical disease between January 2014 and December 2019. Clinical, cytology, colposcopy, and pathology results were evaluated to identify independent predictive factors associated with CIN 1/negative LEEP results.
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
Reumatol Clin (Engl Ed)
November 2020
Article Synopsis
- The study aimed to analyze the effects of baricitinib (BARI) and tocilizumab (TCZ) treatments on patients hospitalized with COVID-19-related interstitial pneumonia, focusing on their outcomes 30 days post-discharge.
- A total of 60 patients were reviewed, with findings indicating that those treated with BARI had lower ICU admission rates and fewer deaths compared to those treated with TCZ, suggesting varying effectiveness between treatments.
- The researchers concluded that BARI and TCZ are safe options for treating COVID-19-related issues, potentially beneficial for patients with severe cases indicated by low oxygenation levels.
Maca (Lepidium meyenii) is a herbaceous plant grown at over 4,000 m in Peru. It has been studied worldwide for its properties on fertility. Previous studies have assessed maca effects on semen quality, but there is need of randomised, double-blind trials in order to make clinical decisions.
View Article and Find Full Text PDFObjectives: The human papilloma virus (HPV) test is recommended in the posttreatment follow-up of cervical intraepithelial neoplasia. The aim of the study was to assess whether the intraoperative HPV (IOP-HPV) test had a similar diagnostic accuracy that HPV test performed at 6 months to predict high-grade squamous intraepithelial lesion (HSIL) recurrence.
Materials And Methods: In a prospective cohort study, 304 women diagnosed with HSIL by biopsy and/or endocervical curettage before treatment and/or confirmation in the histological specimen were included.